Gryssell Rodriguez
CIMAvax-EGF Manufacturing Manager at the Centro de InmunologÃa Molecular (Center for Molecular Immunology)
Articles
Manufacturing Process Development for an Epidermal Growth Factor-Based Cancer Vaccine
Beatriz Garcia;Aurora Tamara Garcia;Gryssell Rodriguez;Tania Crombet;Alejandro Portillo;Ariadna Cuevas;Lisel Viña;Gisela Gonzalez;Ernesto Chico;Loany Calvo;Airama Albisa
October 2nd 2008The Center for Molecular Immunology (Havana, Cuba) has been working on a novel cancer immunotherapy targeting the epidermal growth factor (EGF). The vaccine is composed of a chemical conjugate of EGF and a carrier protein (rP64k), designed to trigger an anti-EGF antibody response. The results of studies of molecular characterization, immunogenic activity, and clinical data are presented here.
Latest Updated Articles
Published: September 11th 2024 | Updated: September 18th 2024
CPHI Pharma Award Finalists Announced for 2024
Published: March 27th 2024 | Updated: June 28th 2024
AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product
Published: December 9th 2024 | Updated: December 21st 2024
Recap Key Industry Trends for Viral Clearance and NGS
Published: December 7th 2024 | Updated: December 21st 2024
Enhancing Quality Through Training
Published: July 20th 2020 | Updated: December 21st 2024
Contact BioPharm International Editors
Published: July 19th 2020 | Updated: December 21st 2024
Editorial Information: BioPharm International Submission Guidelines and Editorial Calendars
